Kidney patients with a very limited residual kidney function usually receive hemodialysis treatment. The problem is that the currently used technique is not able to clear the blood from all toxins. Especially the toxins with a large molecular weight and toxins bound to proteins cannot be removed. Because these toxins remain in the blood, the patients’ health and well-being are (increasingly) impaired. Relitech has invented and patented a method that can improve this: adjunctive blood detoxification (ABD).
In the ABD, toxins are selectively captured by aptamers. Aptamers are short strands of DNA or RNA that specifically bind the toxin of interest. In this way, toxins that usually remain in the blood after hemodialysis will be removed by the ABD, positioned in the blood flow leaving the hemodialysis device. We are currently working on a proof-of-concept in the MIND project .